OET and Eden Biodesign sign co-marketing agreement
OET will offer customers access to Eden Biodesign process development services
Oxford Expression Technologies (OET), a provider of baculovirus-based protein expression products has signed a co-marketing agreement with Eden Biodesign.
Under the agreement, OET will offer its customers access to Eden Biodesign's process development, clinical trial cGMP manufacturing and analytical development services. In return, Eden Biodesign's customers will have access to OET's baculovirus capabilities.
OET said its customers would benefit from a smooth transition between optimisation of expression and cGMP production and scale-up and the ability to transfer projects intended for clinical development to Eden Biodesign's services offered from its EMEA inspected facilities in Liverpool, UK.
Eden Biodesign's customers will be able to take advantage of OET's experience in troubleshooting baculovirus expression; the use of flashBAC technology to increase protein yield in difficult to express proteins; and the development of a protocol for optimal expression of their proteins.
James Bernard, ceo of OET, said: "This partnership will provide customers with unprecedented choice and flexibility."
Crawford Brown, ceo of Eden Biodesign, added: "By collaborating with OET, we can help the increasing number of biotechnology and pharmaceutical companies who are interested in evaluating the performance of their biotherapeutic and vaccine products using this exciting technology to progress rapidly into and through clinical development."
